Omiloxetine
| |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C27H25F2NO4 |
Molar mass | 465.489 g/mol |
3D model (JSmol) | |
Density | 1.3±0.1 g/cm3 |
Melting point | 228.65 °C (443.57 °F) |
Boiling point | 587.2 °C (1,089.0 °F) |
Solubility in water | 0.0015 mg/mL (20 °C) |
| |
|
Omiloxetine (omiloextinum, omiloxetino INN)[1]:212-213 was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.[2][3]
References
- ↑ WHO Drug Information, Vol. 10, No. 4, 1996 Proposed INN: List 76
- ↑ Terencio, Jose (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Retrieved 2012-05-19.
- ↑ De Lecea, Dr Carlos (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Retrieved 2012-05-19.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.